This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Feb;30(2):606.

doi: 10.1038/s41591-022-02070-0.

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Collaborators, Affiliations

Collaborators

Affiliations

¹ New York University Langone Health and The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York, NY, USA.
² Vaccinex, Inc., Research, Rochester, NY, USA.
³ IXICO, London, UK.
⁴ WCG Statistics Collaborative, Inc., Washington, DC, USA.
⁵ University of Rochester Medical Center, Rochester, NY, USA.
⁶ Siemers Integration LLC, Zionsville, IN, USA.
⁷ Vaccinex, Inc., Research, Rochester, NY, USA. mzauderer@vaccinex.com.

PMID: 36195687
PMCID: PMC10878960
DOI: 10.1038/s41591-022-02070-0

Published Erratum

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Andrew Feigin et al. Nat Med. 2024 Feb.

. 2024 Feb;30(2):606.

doi: 10.1038/s41591-022-02070-0.

Authors

Collaborators

Affiliations

¹ New York University Langone Health and The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York, NY, USA.
² Vaccinex, Inc., Research, Rochester, NY, USA.
³ IXICO, London, UK.
⁴ WCG Statistics Collaborative, Inc., Washington, DC, USA.
⁵ University of Rochester Medical Center, Rochester, NY, USA.
⁶ Siemers Integration LLC, Zionsville, IN, USA.
⁷ Vaccinex, Inc., Research, Rochester, NY, USA. mzauderer@vaccinex.com.

PMID: 36195687
PMCID: PMC10878960
DOI: 10.1038/s41591-022-02070-0

No abstract available

PubMed Disclaimer

Erratum for

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.

Publication types

Actions